Global Dyslipidemia Drugs Market 2017-2021
- SKU ID : TNV-IRTNTR12273 10543560
- |
- Publishing Date: 15-Mar-2017
- |
- Region: Global
- |
- No. of pages: 70
ABSTRACT
About Dyslipidemia Drugs
Lipid refers to fat comprising proteins and carbohydrates. Cholesterol and triglycerides are lipids that are stored in the human body and serve as a source of energy. Dyslipidaemia is the imbalance in the lipid level in the bloodstream. It is characterized by high levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the blood. High cholesterol levels can cause cardiovascular diseases (CVD) such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL. Blood cholesterol contains individual components such as LDL-C and high-density lipoprotein cholesterol (HDL-C). Low-density lipoprotein (LDL) carries cholesterol to the body while high-density lipoprotein (HDL) removes cholesterol from the cells by reversing cholesterol transport to the liver. Due to their distinct roles, these components are individually assessed to determine the dyslipidemic status of an individual.
Technavio’s analysts forecast the global dyslipidemia drugs market to grow at a CAGR of 5.27% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global dyslipidemia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Dyslipidemia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• Merck
• Pfizer
• Sanofi
Other prominent vendors
• Alnylam Pharmaceuticals
• Amarin Corporation
• Amgen
• Bristol-Myers Squibb
• Catabasis Pharmaceuticals
• Cerenis
• Cipla
• CJ HealthCare
• CKD Bio
• Daewoong Pharmaceutical
• Daiichi Sankyo
• Eli Lilly
• Esperion Therapeutics
• GlaxoSmithKline
• JW Pharmaceuticals
• Kadmon Pharmaceuticals
• Lupin Pharmaceuticals
Market driver
• Change in ATP guidelines for management of hypercholesterolemia.
• For a full, detailed list, view our report
Market challenge
• Drawbacks associated with current therapies.
• For a full, detailed list, view our report
Market trend
• Increased uptake of OTC drugs.
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
About Dyslipidemia Drugs
Lipid refers to fat comprising proteins and carbohydrates. Cholesterol and triglycerides are lipids that are stored in the human body and serve as a source of energy. Dyslipidaemia is the imbalance in the lipid level in the bloodstream. It is characterized by high levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the blood. High cholesterol levels can cause cardiovascular diseases (CVD) such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL. Blood cholesterol contains individual components such as LDL-C and high-density lipoprotein cholesterol (HDL-C). Low-density lipoprotein (LDL) carries cholesterol to the body while high-density lipoprotein (HDL) removes cholesterol from the cells by reversing cholesterol transport to the liver. Due to their distinct roles, these components are individually assessed to determine the dyslipidemic status of an individual.
Technavio’s analysts forecast the global dyslipidemia drugs market to grow at a CAGR of 5.27% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global dyslipidemia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Dyslipidemia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• Merck
• Pfizer
• Sanofi
Other prominent vendors
• Alnylam Pharmaceuticals
• Amarin Corporation
• Amgen
• Bristol-Myers Squibb
• Catabasis Pharmaceuticals
• Cerenis
• Cipla
• CJ HealthCare
• CKD Bio
• Daewoong Pharmaceutical
• Daiichi Sankyo
• Eli Lilly
• Esperion Therapeutics
• GlaxoSmithKline
• JW Pharmaceuticals
• Kadmon Pharmaceuticals
• Lupin Pharmaceuticals
Market driver
• Change in ATP guidelines for management of hypercholesterolemia.
• For a full, detailed list, view our report
Market challenge
• Drawbacks associated with current therapies.
• For a full, detailed list, view our report
Market trend
• Increased uptake of OTC drugs.
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
